Cytokinetics (CYTK) News Today $48.87 +2.13 (+4.56%) (As of 12/20/2024 05:31 PM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Why Cytokinetics Stock Was a Nearly 5% Winner TodayDecember 20 at 5:25 PM | fool.comHC Wainwright Reiterates "Buy" Rating for Cytokinetics (NASDAQ:CYTK)HC Wainwright reaffirmed a "buy" rating and set a $120.00 target price on shares of Cytokinetics in a report on Friday.December 20 at 10:27 AM | marketbeat.comCytokinetics Announces Sanofi Acquired Rights to Develop and Commercialize Aficamten in Greater ChinaDecember 20 at 12:00 AM | globenewswire.comCalculating The Fair Value Of Cytokinetics, Incorporated (NASDAQ:CYTK)December 19 at 7:08 AM | finance.yahoo.comFranklin Resources Inc. Sells 1,820,114 Shares of Cytokinetics, Incorporated (NASDAQ:CYTK)Franklin Resources Inc. lessened its stake in Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) by 77.2% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 536,447 shares of the biopharmaceutical company's stock after selliDecember 19 at 5:15 AM | marketbeat.comCytokinetics price target raised to $82 from $80 at RBC CapitalDecember 18 at 4:05 PM | markets.businessinsider.comCytokinetics (NASDAQ:CYTK) Given New $82.00 Price Target at Royal Bank of CanadaRoyal Bank of Canada raised their price target on shares of Cytokinetics from $80.00 to $82.00 and gave the company an "outperform" rating in a report on Wednesday.December 18 at 10:46 AM | marketbeat.comInsider Selling: Cytokinetics, Incorporated (NASDAQ:CYTK) Director Sells 742 Shares of StockDecember 17, 2024 | insidertrades.comGeode Capital Management LLC Raises Position in Cytokinetics, Incorporated (NASDAQ:CYTK)Geode Capital Management LLC lifted its stake in shares of Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) by 4.0% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 2,848,584 shares of the biopharmaceutical company's stock after buyinDecember 17, 2024 | marketbeat.comWendall Wierenga Sells 742 Shares of Cytokinetics, Incorporated (NASDAQ:CYTK) StockCytokinetics, Incorporated (NASDAQ:CYTK - Get Free Report) Director Wendall Wierenga sold 742 shares of the business's stock in a transaction dated Monday, December 16th. The stock was sold at an average price of $48.61, for a total value of $36,068.62. Following the completion of the transaction, the director now owns 24,559 shares in the company, valued at approximately $1,193,812.99. This trade represents a 2.93 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.December 16, 2024 | marketbeat.comCytokinetics, Incorporated (NASDAQ:CYTK) Director Sells $89,747.60 in StockDecember 13, 2024 | insidertrades.comCytokinetics, Incorporated (NASDAQ:CYTK) Receives $83.93 Average Target Price from AnalystsDecember 11, 2024 | americanbankingnews.comInsider Sell: Fady Malik Sells 7,300 Shares of Cytokinetics Inc (CYTK)December 10, 2024 | gurufocus.comTwo Sigma Advisers LP Purchases New Position in Cytokinetics, Incorporated (NASDAQ:CYTK)Two Sigma Advisers LP purchased a new position in Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 214,700 shares of the biopharmaceutical company's stoDecember 10, 2024 | marketbeat.comCytokinetics, Incorporated (NASDAQ:CYTK) Receives Average Rating of "Moderate Buy" from BrokeragesCytokinetics, Incorporated (NASDAQ:CYTK - Get Free Report) has been given an average recommendation of "Moderate Buy" by the sixteen research firms that are covering the firm, MarketBeat Ratings reports. Four research analysts have rated the stock with a hold recommendation and twelve have assignedDecember 8, 2024 | marketbeat.comBNP Paribas Financial Markets Sells 15,629 Shares of Cytokinetics, Incorporated (NASDAQ:CYTK)BNP Paribas Financial Markets cut its holdings in shares of Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) by 27.9% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 40,292 shares of the biopharmaceutDecember 7, 2024 | marketbeat.comWhy Is Cytokinetics (CYTK) Down 9.7% Since Last Earnings Report?December 6, 2024 | finance.yahoo.comTruist Financial Sticks to Its Buy Rating for Cytokinetics (CYTK)December 6, 2024 | markets.businessinsider.comJanus Henderson Group PLC Has $60.40 Million Stake in Cytokinetics, Incorporated (NASDAQ:CYTK)Janus Henderson Group PLC grew its position in Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) by 17.2% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,143,830 shares of thDecember 6, 2024 | marketbeat.comRedmile Group LLC Sells 14,751 Shares of Cytokinetics, Incorporated (NASDAQ:CYTK)Redmile Group LLC lowered its holdings in shares of Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) by 13.2% during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 97,116 shares of the biopharmaceutical company's stock after selling 14,751 shaDecember 5, 2024 | marketbeat.comMelqart Asset Management UK Ltd Cuts Stake in Cytokinetics, Incorporated (NASDAQ:CYTK)Melqart Asset Management UK Ltd lessened its stake in shares of Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) by 27.7% in the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 1,212,258 shares of the biopharmaceutical company's stock afterDecember 4, 2024 | marketbeat.comHighVista Strategies LLC Invests $531,000 in Cytokinetics, Incorporated (NASDAQ:CYTK)HighVista Strategies LLC acquired a new stake in shares of Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) in the third quarter, according to the company in its most recent 13F filing with the SEC. The fund acquired 10,055 shares of the biopharmaceutical company's stock, valued at approximatDecember 4, 2024 | marketbeat.comCytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)December 3, 2024 | globenewswire.comCytokinetics Announces Start of COMET-HF, a Confirmatory Phase 3 Clinical Trial of Omecamtiv Mecarbil in Patients with Symptomatic Heart Failure with Severely Reduced Ejection FractionDecember 3, 2024 | globenewswire.comCytokinetics' application for aficamten accepted by FDADecember 3, 2024 | msn.comCytokinetics Gains Momentum: Aficamten’s Regulatory Progress and Market Potential Propel ‘Buy’ RatingDecember 3, 2024 | markets.businessinsider.comCytokinetics’ Aficamten Gains Momentum with FDA and Promising SEQUOIA-HCM Trial Results, Justifying Buy RatingDecember 3, 2024 | markets.businessinsider.comErste Asset Management GmbH Invests $3.16 Million in Cytokinetics, Incorporated (NASDAQ:CYTK)Erste Asset Management GmbH acquired a new position in shares of Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) during the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 60,450 shares of the biopharmaceutical company'sDecember 3, 2024 | marketbeat.comCytokinetics, Incorporated (NASDAQ:CYTK) CEO Robert I. Blum Sells 5,000 SharesDecember 3, 2024 | insidertrades.comThe Manufacturers Life Insurance Company Purchases 41,057 Shares of Cytokinetics, Incorporated (NASDAQ:CYTK)The Manufacturers Life Insurance Company raised its position in Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) by 23.6% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 214,832 shares of the biopharmaceuDecember 3, 2024 | marketbeat.comCytokinetics to Participate in December Investor ConferencesDecember 2, 2024 | globenewswire.comCytokinetics Announces FDA Acceptance of New Drug Application for Aficamten for the Treatment of Obstructive Hypertrophic CardiomyopathyDecember 2, 2024 | globenewswire.comVestal Point Capital LP Sells 575,000 Shares of Cytokinetics, Incorporated (NASDAQ:CYTK)Vestal Point Capital LP lessened its holdings in shares of Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) by 27.7% during the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 1,500,000 shares of the biopharmaceutical company's stock after selling 575,000 shaNovember 29, 2024 | marketbeat.comCharles Schwab Investment Management Inc. Buys 395,709 Shares of Cytokinetics, Incorporated (NASDAQ:CYTK)Charles Schwab Investment Management Inc. grew its stake in Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) by 42.7% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,321,391 shares of the biopharmaceuNovember 29, 2024 | marketbeat.comRBC Capital Sticks to Its Buy Rating for Cytokinetics (CYTK)November 28, 2024 | markets.businessinsider.comCytokinetics, Incorporated (NASDAQ:CYTK) Shares Sold by Great Point Partners LLCGreat Point Partners LLC reduced its stake in shares of Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) by 33.4% during the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 316,000 shares of the biopharmaceutical company's stock after selling 158,202 shares dNovember 27, 2024 | marketbeat.comAlgert Global LLC Sells 22,738 Shares of Cytokinetics, Incorporated (NASDAQ:CYTK)Algert Global LLC decreased its holdings in shares of Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) by 31.8% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 48,670 shares of the biopharmaceutical company's stocNovember 27, 2024 | marketbeat.comInsider Sell Alert: Fady Malik Sells 7,300 Shares of Cytokinetics Inc (CYTK)November 26, 2024 | gurufocus.comCytokinetics, Incorporated (NASDAQ:CYTK) Shares Purchased by Massachusetts Financial Services Co. MAMassachusetts Financial Services Co. MA raised its position in Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) by 24.8% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 344,448 shares of the biopNovember 26, 2024 | marketbeat.comIntech Investment Management LLC Makes New $1.73 Million Investment in Cytokinetics, Incorporated (NASDAQ:CYTK)Intech Investment Management LLC bought a new stake in Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor bought 32,671 shares of the biopharmaceutical company'sNovember 26, 2024 | marketbeat.comWestfield Capital Management Co. LP Purchases 339,373 Shares of Cytokinetics, Incorporated (NASDAQ:CYTK)Westfield Capital Management Co. LP increased its holdings in shares of Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) by 38.9% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 1,212,886 shares of the biopharmaceutical cNovember 25, 2024 | marketbeat.comSwiss National Bank Buys 20,000 Shares of Cytokinetics, Incorporated (NASDAQ:CYTK)Swiss National Bank lifted its stake in shares of Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) by 10.2% during the third quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 215,500 shares of the biopharmaceutical company's stock after purchasing anNovember 24, 2024 | marketbeat.comOntario Teachers Pension Plan Board Takes Position in Cytokinetics, Incorporated (NASDAQ:CYTK)Ontario Teachers Pension Plan Board bought a new position in shares of Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) during the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor bought 11,212 shares of the biopharmaceutical company's stock, valuNovember 22, 2024 | marketbeat.comCytokinetics Secures Strategic Partnership with Bayer: Analyst Recommends Buy RatingNovember 21, 2024 | markets.businessinsider.comCytokinetics price target raised to $103 from $99 at MizuhoNovember 21, 2024 | markets.businessinsider.comWhy Is Cytokinetics, Incorporated (CYTK) Among the Worst Performing Biotech Stocks in 2024?November 21, 2024 | msn.comMizuho Forecasts Strong Price Appreciation for Cytokinetics (NASDAQ:CYTK) StockMizuho raised their target price on Cytokinetics from $99.00 to $103.00 and gave the company an "outperform" rating in a research note on Thursday.November 21, 2024 | marketbeat.comCytokinetics, Bayer in Japan Licensing Pact for AficamtenNovember 20, 2024 | marketwatch.comCytokinetics’ Hold Rating Amid Bayer Partnership and Acquisition UncertaintyNovember 20, 2024 | markets.businessinsider.comCytokinetics Gains ‘Buy’ Rating Due to Strategic Collaborations and Potential FDA ApprovalNovember 20, 2024 | markets.businessinsider.com Get Cytokinetics News Delivered to You Automatically Sign up to receive the latest news and ratings for CYTK and its competitors with MarketBeat's FREE daily newsletter. Email Address URGENT: This Altcoin Opportunity Won’t Wait – Act Now (Ad)Crypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight. >> Register for the Workshop Now CYTK Media Mentions By Week CYTK Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CYTK News Sentiment▼0.850.61▲Average Medical News Sentiment CYTK News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CYTK Articles This Week▼1310▲CYTK Articles Average Week Get Cytokinetics News Delivered to You Automatically Sign up to receive the latest news and ratings for CYTK and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Teva Pharmaceutical Industries News BeiGene News Moderna News Viatris News Summit Therapeutics News Genmab A/S News Dr. Reddy's Laboratories News Sarepta Therapeutics News Catalent News Vaxcyte News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CYTK) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cytokinetics, Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Share Cytokinetics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
